After Roe, Men Might Finally Get Better Birth Control

WIRED magazine explores the development of reliable contraception for men, including the Population Council's Nestorone®/Testosterone gel.

World Population Day Shines a Spotlight on Inequities

The Council's Abriendo Oportunidades project is featured in the New Security Beat, the blog of the Environmental Change and Security Program at the Wilson Center.

Debate: Is Reproductive Health Safe in the Global South?

Rajib Acharya, senior associate at the Population Council India, joins an expert panel to debate whether reproductive health services in the global South are in jeopardy in light of the U.S. Supreme Court's decision to abolish the right to abortion.

Changing Attitudes is an Important First Step Towards Eradicating FGM, but It Isn’t Enough

In The Telegraph, activist Nimco Ali cites the Population Council’s comprehensive evidence review on the effectiveness of interventions designed to prevent or respond to female genital mutilation.

Double Agents in Global Health

Thoai Ngo, Vice President of Social and Behavioral Science Research, shares his perspective on global health as a "double agent" straddling two worlds. Ngo contributes insights to an essay by Madhukar Pai, Canada Research Chair in Epidemiology & Global Health at McGill University.

Skill Building of Rohingya and Host Community Adolescents and Youth: Opportunities and Challenges

The Council’s Ashish Bajracharya and Ubaidur Rob joined partners in a roundtable discussion on the needs and workforce potential of adolescents in the Rohingya community. The conversation was summarized in The Daily Star.

Male Birth Control: A Promising New Trial in California, and Why Reproductive Autonomy Matters

Council scientists are developing a novel reversible contraceptive gel for men, Nestorone®/Testosterone (NES/T), designed to be absorbed through the skin with minimal side effects. This article discusses the phase two clinical trials of the gel, started in 2018.

Expanding Access and Instilling Faith in Vaccines

In a Letter to the Editor in the New York Times, James Sailer, Executive Director of the Population Council’s Center for Biomedical Research, makes the case for maintaining the intellectual property system, which rewards research and development innovation.